openPR Logo
Press release

Aptinyx Inc. (NASDAQ: APTX) Investor Investigation over potential Wrongdoing

05-05-2020 03:20 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

An investigation on behalf of investors in Aptinyx Inc. (NASDAQ: APTX) shares over potential wrongdoing at Aptinyx Inc.

An investigation on behalf of investors in Aptinyx Inc. (NASDAQ: APTX) shares over potential wrongdoing at Aptinyx Inc.

An investigation on behalf of investors in shares of Aptinyx Inc. (NASDAQ: APTX) was announced over potential breaches of fiduciary duties by certain officers and directors at Aptinyx Inc.

Investors who purchased shares of Aptinyx Inc. (NASDAQ: APTX) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm concerns whether certain Aptinyx Inc. directors breached their fiduciary duties and caused damage to the company and its shareholders.

Evanston, IL based Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. Aptinyx Inc. completed its initial publis offering ("IPO") on June 21, 2018, offering $16.00 per share for net proceeds of $92.2 million. However, since the IPO shares of Aptinyx Inc. (NASDAQ: APTX) declined to as low as $2.96 per share on August 26, 2019.

Those who purchased shares of Aptinyx Inc. (NASDAQ: APTX) have certain options and should contact the Shareholders Foundation.

Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Aptinyx Inc. (NASDAQ: APTX) Investor Investigation over potential Wrongdoing here

News-ID: 2033814 • Views: 540

More Releases from Shareholders Foundation

NS8 Inc. Former Employee Alert: Investigation over possible Violations of Securi …
An investigation was announced over potential securities laws violations by NS8 Inc. and certain of its directors and officers in connection with certain financial statements. Former employees of NS8 Inc. should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on whether certain statements by NS8 Inc. regarding its business, its prospects and its operations were materially false and misleading
Update in Lawsuit for Investors in shares of The RealReal, Inc. (NASDAQ: REAL)
A lawsuit is pending for investors in The RealReal, Inc. (NASDAQ: REAL) over alleged violations of Federal Securities Laws by The RealReal, Inc. in connection RealReal’s June 2019 initial public stock offering (the “IPO”). Investors who purchased shares of The RealReal, Inc. (NASDAQ: REAL) have certain options and for certain investors are short and strict deadlines running. Deadline: January 24, 2020. NASDAQ: REAL investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com
Deadline on Sept. 28th upcoming in Lawsuit for Investors in shares of FirstEnerg …
The Shareholders Foundation announced that a deadline is coming up on September 28, 2020 in the lawsuit filed for certain investors of FirstEnergy Corp. (NYSE: FE) over alleged securities laws violations by FirstEnergy Corp. Investors who purchased shares of FirstEnergy Corp. (NYSE: FE) have certain options and there are strict and short deadlines running. Deadline: September 28, 2020. NYSE: FE stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858)
Investigation announced for Long-Term Investors in shares of Co-Diagnostics, Inc …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Co-Diagnostics, Inc.. Investors who are current long term investors in Co-Diagnostics, Inc. (NASDAQ: CODX) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in NASDAQ: CODX stocks follows a lawsuit filed against Co-Diagnostics, Inc over

All 5 Releases


More Releases for Aptinyx

Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, Gross Margi …
This report also researches and evaluates the impact of Covid-19 outbreak on the Chemotherapy Induced Peripheral Neuropathy Treatment industry, involving potential opportunity and challenges, drivers and risks. We present the impact assessment of Covid-19 effects on Chemotherapy Induced Peripheral Neuropathy Treatment and market growth forecast based on different scenario (optimistic, pessimistic, very optimistic, most likely etc.).   Scope of the Report: The report presents the market outlook for the Indian Phospho Gypsum product from the year 2020 to
Fibromyalgia Treatment Market Segmented by Product, Top Manufacturers, Geography …
The global Fibromyalgia Treatment market is carefully researched in the report while largely concentrating on top players and their business tactics, geographical expansion, market segments, competitive landscape, manufacturing, and pricing and cost structures. Each section of the research study is specially prepared to explore key aspects of the global Fibromyalgia Treatment market. For instance, the market dynamics section digs deep into the drivers, restraints, trends, and opportunities of the global
Post-Traumatic Stress Disorder (PTSD) Pipeline Review, H1 2019 by: Actinogen Med …
Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2019. Summary: Post-traumatic stress disorder (PTSD) is a mental health condition that's triggered by a terrifying event either experiencing it or witnessing it. Symptoms include flashbacks, nightmares and severe anxiety, as well as uncontrollable thoughts about the event. Treatment includes antidepressants, anti-anxiety and cognitive therapy. Report Highlights: Post-Traumatic Stress Disorder (PTSD) market based on elite players, present, past and futuristic data which will offer
Chemotherapy Induced Peripheral Neuropathy Treatment Market 2019 |by Trends Anal …
MarketResearchNest.com published an Exclusive Research Report on “Global Chemotherapy Induced Peripheral Neuropathy Treatment Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024” that highlights the in-depth market analysis and covers significant data with future prospects of the market. CIPN is a common adverse effect of several cancer therapies including taxanes and platinum drugs. Symptoms include decreased sensation and tingling of the hands and feet, severe pain, numbness and muscle
Chemotherapy Induced Peripheral Neuropathy Treatment Market will reach 1880 mill …
New report published by Global Info Research which offers insights on the global Chemotherapy Induced Peripheral Neuropathy Treatment market. CIPN is a common adverse effect of several cancer therapies including taxanes and platinum drugs. Symptoms include decreased sensation and tingling of the hands and feet, severe pain, numbness and muscle weakness, all of which can occur during cancer treatment, and frequently persist after chemotherapy has ended.
Chemotherapy Induced Peripheral Neuropathy Treatment Market Outlook and Forecast …
The “Global Chemotherapy Induced Peripheral Neuropathy Treatment Analysis to 2025” is a specialized and in-depth study of the Chemotherapy Induced Peripheral Neuropathy Treatment industry with a focus on the global market trend. The report aims to provide an overview of global Chemotherapy Induced Peripheral Neuropathy Treatment with detailed market segmentation by component, type, application and geography. The global Chemotherapy Induced Peripheral Neuropathy Treatment market is expected to witness high growth